SCHEMBL26906640

SCHEMBL26906640

CC(=O)Nc1cc(Cl)c(Cl)cc1Nc1nc(Nc2ccc(N3CCOCC3)nc2)ncc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKMYT1 Q99640 2/20 0.55
▸ INSR P06213 1/20 0.55
▸ IGF1R P08069 1/20 0.55
▸ PTK2 Q05397 1/20 0.55
▸ PTK2B Q14289 1/20 0.55
▸ MAPK9 P45984 4/20 0.54
▸ MAPK10 P53779 4/20 0.54
▸ MAPK8 P45983 2/20 0.54
▸ SLC2A1 P11166 1/20 0.54
▸ EGFR P00533 4/20 0.54
▸ ALK Q9UM73 3/20 0.54
▸ ROS1 P08922 1/20 0.54
▸ CCNK O75909 1/20 0.54
▸ CCNA2 P20248 1/20 0.54
▸ CDK2 P24941 1/20 0.54
▸ CCND3 P30281 1/20 0.54
▸ CDK9 P50750 1/20 0.54
▸ CDK6 Q00534 1/20 0.54
▸ MAP3K7 O43318 2/20 0.53
▸ MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29904681 1.00 PKMYT1 (0.55) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL19831454 0.79 PTK2 (0.64) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL26906721 0.77 CDK9 (0.59) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL29904658 0.77 CDK9 (0.59) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL29904686 0.76 CCNK (0.60) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL29114906 0.75 — —
SCHEMBL50482 0.74 MAPT (0.69) RAB9A
SCHEMBL28860458 0.73 EGFR (0.54) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL13321204 0.72 CCNK (0.60) PKMYT1INSRIGF1RPTK2PTK2B
SCHEMBL28980964 0.72 MAP3K7 (0.72) IGF1RPTK2MAPK9MAPK8SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP claimed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 PKMYT1 357/4885INSR 607/4885IGF1R 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback